Introduction
============

There is evidence that many patients are unable to use their pressurised metered-dose inhaler devices (pMDIs) correctly,^[@bib1; @bib2; @bib3]^ and we confirmed this in a recent study where over 60% of patients were unable to use their pMDI correctly after being shown how on three occasions.^[@bib4]^ In practice it is logical that inhalers are prescribed only after patients have received training and demonstrated their ability to use the device. Furthermore, according to UK guidelines^[@bib5]^ as well as the Global Strategy for Asthma Management and Prevention (GINA) strategy document,^[@bib6]^ inhaler technique should be tested in all patients, particularly those with poorly controlled asthma.^[@bib3]^ Age^[@bib7]^ and gender^[@bib2]^ have also been shown to influence the ability of patients to use their pMDI correctly. It is therefore of concern that a recent analysis of 6 years of sales of inhaler devices revealed that nearly 50% were for pMDIs.^[@bib8]^ There is also evidence that poor inhaler technique results in a decreased response to medication^[@bib9]^ and poor asthma control,^[@bib10; @bib11; @bib12]^ and that correction of a patient\'s ability to use their device improves control and compliance.^[@bib12]^

The Improving the Management of Patients Asthma and COPD Treatment (IMPACT) service, started in March 2009, works with primary care practices in the UK. It includes a service providing clinical asthma reviews of patients by trained nurses according to protocols agreed with the practices based on the UK National Asthma Guidelines.^[@bib5]^ Having agreed protocols, each participating practice invites patients to attend the clinics. At the time of writing, around 400 practices have used the service following introduction to the practice by the visiting Teva UK Ltd pharmaceutical representatives as a non-promotional service.

Data collected systematically during the asthma reviews offer a unique opportunity to evaluate aspects of care, including some of the factors affecting asthma control. As part of our service evaluation of the clinics, we assessed the relationship between asthma control and patients\' ability to use their pMDIs. In this paper we describe the relationship between asthma control and aspects of inhaler technique in those prescribed pMDIs for their asthma treatment.

Methods
=======

Practices agreeing to the IMPACT service invited selected patients of theirs to attend for a structured asthma review by nurses trained to diploma level in this field. All patients at British Thoracic Society treatment steps 1 and 2 and, in some cases, step 3 were eligible for their asthma to be reviewed (see [Figure 1](#fig1){ref-type="fig"}), irrespective of the patient\'s level of control. However, subsequent refinement of selection was offered as an option for the practices, based mainly on a number of factors identified by a search of the practice\'s computerised medical record computer systems using 77 predetermined clinical parameters (including prescribing, particularly of short-acting β~2~-agonist bronchodilators) and healthcare utilisation data. Patients were also sent asthma control questionnaires --- the so called 'Royal College of Physicians 3-Questions').^[@bib13]^ In most instances all patients from the practice asthma register were invited for review unless, for example, they had been reviewed by the practice in the few weeks prior to initiation of the service.

During the asthma review, all patients using pMDIs had at least two assessments both by observation by the nurse and assessment using the Vitalograph Aerosol Inhalation Monitor (AIM),^[@bib4],[@bib14],[@bib15]^ with provision of education on inhaler technique after testing if appropriate. The AIM measures inspiratory flow, ongoing flow, synchronisation, and breath-holding. A colour-coded response indicates the quality of three parameters of the patient\'s inhaler technique: Inspiratory flow between 10 and 50L/min: the AIM associates flow with the firing (actuation) of the placebo canister. Firing is acceptable when the canister is depressed while the flow rate is within the acceptable (green) range.Synchronisation: the green light shows when the patient has achieved the correct flow (i.e. between 10 and 50L/min) for at least 1.5 seconds of the 3 seconds following firing (actuating) the placebo device.Breath-holding: breath-hold at end of inspiration for at least 5 seconds.

The flowhead (i.e. a 'dummy' pMDI) is calibrated to the instrument. All flows have a tolerance of ±5L/min (personal communication, Vitalograph).

All patients previously prescribed and currently using pMDIs had at least two assessments using AIM, with inhaler technique education if appropriate. Visual observation and use of the Clement-Clarke In-Check™ device was used by the nurses in parallel with the AIM assessment. This information was used by the nurses when teaching patients to use their device correctly. Any changes to medication were implemented by the nurses according to the pre-agreed practice protocol. Following clinic assessment, all patients were discussed in detail by the nurses with the patient\'s GP who decided on future management.

In addition, all patients had their asthma control assessed using the parameters of asthma control described in the GINA strategy,^[@bib6]^ which includes the presence of asthma symptoms in the day or night; limitation of activity; use of reliever medication; and lung function in the previous week. This system for assessing asthma control is a working scheme based on current opinion and has not been formally validated. However, this classification has been shown to correlate well with the Asthma Control Test and with assessment of asthma control according to the US National Expert Panel Report 3 guidelines.^[@bib6]^

Patients' asthma was classified as controlled, partly controlled, or uncontrolled using this GINA tool. Controlled asthma is defined according to GINA as follows: \<2 episodes of daytime symptoms, \<2 episodes of using reliever medication, no night time symptoms, no limitation of activity, and normal lung function in the previous week.^[@bib6]^

All information processed was solely for the purpose of carrying out the service and complied fully with the Nursing and Midwifery Council (NMC) Code of Conduct (Nursing Staff),^[@bib16]^ ABPI Code of Practice 2008,^[@bib17]^ Caldicott Principles,^[@bib18]^ and the UK Data Protection Act 1998.^[@bib19]^

All identifiable patient data remained in the practice together with any reports generated. As this service was provided by National Services for Health Improvement (NSHI) at the request of and in accordance with agreed practice protocols, ethics approval was not deemed to be necessary.

Data analysis
-------------

The results of the inhaler technique testing using the AIM machine were analysed by comparing the success or failure of the test against GINA control using the χ^2^ statistic using the cross-tabulation function of SPSS V.18 for Mac.

Results
=======

Asthma patient reviews were performed by the IMPACT nurses on 3,981 patients (46% male) in 15 general practices during 2009. The age distribution of these patients was as follows: 806 (20%) \<16 years, 1,128 (28%) aged 17--45 years, 1,664 (42%) aged 46--75 years, and 374 (9%) aged \>76 years; nine had missing data. Accurate data on reliever and preventer inhaler device prescriptions were available for 3,686 and 2,887 patients, respectively. Reliever devices prescribed included dry powder inhalers (n=316 (9%), comprising Accuhalers, Clickhalers, Diskhalers, Easyhaler, Novolizers, Pulvinal, Turbohalers and Twisthalers) as well as breath-actuated pMDIs (n=469 (13%), comprising Autohaler and Easi-Breathe®). pMDIs alone were prescribed for 2,375 patients (64%) and together with spacers in 525 patients (14%). One patient was on nebulised terbutaline.

Preventer inhaler devices prescribed included dry powder inhalers (n=398 (14%), comprising Accuhalers, Clickhalers, Diskhalers, Easyhalers, Novolizers, Pulvinal, Turbohalers and Twisthalers) as well as breath-actuated devices (n=340 (12%), comprising Autohaler and Easi-Breathe®). pMDIs alone were prescribed for 1,976 patients (68%) and together with spacers in 171 patients (6%). One patient was on nebulised budesonide. Of the available prescribing data, beclometasone dipropionate (BDP) was the most commonly prescribed preventer drug (QVAR® via pMDI and Easi-Breathe®, Clenil® pMDI), comprising 60.2% of the total drugs prescribed for this population. The other 40% of prescriptions for preventer drugs included combination drugs (Seretide™, Symbicort™, and Fostair™), budesonide, fluticasone, and mometasone.

Of the patients who had their inhaler technique tested using the AIM, 58%, 52%, and 38% failed to use the pMDI correctly at the first, second and third tests, respectively. The percentages of patients who failed one or more of the three criteria (flow, synchronisation and breath-holding) for each test are shown in [Table 1](#tbl1){ref-type="table"}.

There was a statistically significant association between asthma control and the aspects of inhaler technique tested. Incorrect inhaler use was found in four times as many patients with uncontrolled asthma and over twice as many patients with partly controlled asthma ([Table 2](#tbl2){ref-type="table"}, p\<0.0001, χ^2^ value 281.19). Significantly more patients who had one or more asthma exacerbations (68%, p=0.03) failed their first inhaler technique test. [Table 3](#tbl3){ref-type="table"} shows the relationship between previous prescriptions of systemic steroids and inhaler technique: 67% of those prescribed a short course of prednisolone in the previous 3 months (p\<0.05; odds ratio (OR) 0.50--0.89) failed their first AIM inhaler technique test when attending the clinic.

As the most commonly prescribed preventer was BDP, comparisons were made between pMDI with pMDI plus spacer, and BDP pMDIs (Clenil and QVAR) with the breath-actuated BDP QVAR Easi-Breathe inhaler. In patients who were using spacers together with their pMDIs, 68% vs. 51% had better control of their asthma ([Table 4](#tbl4){ref-type="table"}, p\<0.0001, χ^2^ value 20.16). Patients using breath-actuated BDP pMDIs (QVAR Easi-Breathe) had significantly better asthma control than those using the same drug via a conventional pMDI (Clenil and QVAR) ([Table 5](#tbl5){ref-type="table"}, p\<0.0001, χ^2^ value 23.199).

Discussion
==========

Main findings
-------------

This real-world service evaluation demonstrated a correlation between patients' inability to use their prescribed pMDI and poor asthma control. In line with national guidelines, inhaler technique and asthma control were assessed at each review. Nearly 60% of the patients in this population and nearly 80% of those with uncontrolled asthma failed to use their prescribed pMDI device correctly when first tested. The data in [Table 3](#tbl3){ref-type="table"} indicate a strong association between failure to use a pMDI and incidence of asthma exacerbations in the previous year; 66% of those who had exacerbations (i.e. required short courses of oral steroids) were unable to use their pMDIs.

We have also demonstrated that a greater proportion of patients using spacers with their pMDIs have better control than those using pMDIs alone (68% vs. 51%). Furthermore, a greater proportion of patients using breath-actuated pMDIs (QVAR Easi-Breathe) have better control than those using conventional pMDIs (64% vs. 46%). While the numbers of patients in this population using spacers and breath-actuated pMDIs were relatively low, there was a statistically significant difference in the numbers attaining asthma control.

Interpretation of findings in relation to previously published work
-------------------------------------------------------------------

While problems have been identified by other researchers in the use of many different types of inhaler devices,^[@bib20],[@bib21]^ pMDIs are the most commonly prescribed device in the UK so our evaluation focused specifically on aspects of technique related to pMDIs. Cost is the main consideration for UK health service managers in directing prescribing by primary care health professionals. This extremely short-sighted view does not take account of other health economic factors related to asthma such as the healthcare utilisation cost of managing acute asthma attacks and hospitalisations as well as the decreased quality of life and lost productivity for individual patients and their families.

These data support the findings of previously published studies associating poor inhaler handling with adverse outcomes. Bateman and colleagues demonstrated that people with uncontrolled asthma are six times more likely to suffer an exacerbation than those whose asthma is controlled.^[@bib22]^ An Italian cross-sectional outpatient study of 1,664 patients with asthma and chronic obstructive pulmonary disease noted an association between inhaler mishandling (dry powder and pMDIs) and increased unscheduled healthcare resource use and poor clinical control.^[@bib3]^ Another study involving 915 French general practitioners who observed over 4,000 patients using their pMDIs found an association between poor technique and uncontrolled asthma.^[@bib11]^

Studies investigating acute asthma and asthma deaths demonstrate under-prescription of systemic steroids for the fatal attack.^[@bib23; @bib24; @bib25; @bib26; @bib27; @bib28; @bib29]^ The proportion of patients with poor inhaler technique prescribed systemic steroids shown in [Table 3](#tbl3){ref-type="table"} therefore probably underestimates the true numbers of patients with poor technique who suffer asthma attacks.

Our data strongly support the recommendations in the UK asthma guidelines,^[@bib5]^ the international GINA strategy documents,^[@bib6]^ as well as the recent NICE Quality Statement 25 on Asthma^[@bib30]^ that patients should not be prescribed pMDIs without first checking their ability to use them. Furthermore, if patients cannot use pMDIs, then a spacer or an alternative device that they can use should be prescribed.^[@bib5],[@bib6]^

Strengths and limitations of this study
---------------------------------------

One weakness of the study is that it was a retrospective analysis of data collected during provision of an asthma review service for general practices and we did not have a control group of practices. We cannot be sure to what extent those with poor asthma control did not adhere to medical advice or were not treated according to the national guidelines; this is a subject for further research.

We could also be criticised for using the GINA control system; however, in addition to the comments in the Methods section, this classification also correlates well with the Asthma Control Questionnaire (which relates to the previous 7 days).^[@bib31]^

This evaluation does not allow for consideration of the relative importance of the three aspects of pMDI inhaler technique (flow, synchronisation, and breath-holding) assessed by the AIM. This may be of importance and for consideration by other researchers; however, as these were objectively measured we believe this composite method is of value.

While there are many aspects of pMDI inhaler technique that patients may get wrong,^[@bib21]^ for pragmatic reasons we formally assessed and reported on the three measures tested by the AIM. However, our nurses also observed patients\' technique and used the In-Check Dial™ device to evaluate and subsequently base their instructions for patients.

The strength of this study is that the asthma reviews were performed by trained asthma nurses and included a very large multicentre dataset representative of general practice patient populations in the UK. Practices selected which patients were invited to attend clinics, and many of these had previously unrecognised poorly controlled asthma; they were appropriately provided with a quality review by a trained asthma nurse.

Implications for future research, policy and practice
-----------------------------------------------------

Given the relationship we have demonstrated between poor inhaler technique and asthma control, there is a clear need for clinicians to ensure patients are able to use their inhalers correctly. A number of studies have demonstrated various methods for achieving this goal. Examples include teaching patients during a hospital admission,^[@bib32]^ opportunistically on repeated outpatient attendance,^[@bib33]^ or when collecting medication from a pharmacist trained in teaching inhaler technique.^[@bib34]^ Actively demonstrating the technique with patients showing their ability seems to work better than simply telling patients or providing a leaflet on how to use their device.^[@bib34],[@bib35]^

Future research involving patients being treated in primary care should include inhaler device usage focused on technical ability in both control and intervention group patients. This research should attempt to identify factors such as age, gender, and the degree to which asthma control is determined by inhaler technique.

We have demonstrated an association between poor pMDI inhaler technique and poor asthma control. Not many studies have done this, so we have highlighted the importance and emphasised the need to check inhaler technique and to take appropriate action to either improve this through education or prescribe a different device. Furthermore, all patients with asthma should have their inhaler technique checked at initial prescription and at every opportunity when consulting.

Conclusions
-----------

Patients who are able to use pMDIs correctly have better asthma control as defined by the GINA strategy document. BDP via a spacer or a breath-actuated device resulted in better asthma control than via a pMDI alone. Patients prescribed pMDIs should be carefully instructed in technique and have their ability to use these devices tested; those unable to use the device should be prescribed a spacer or an alternative device such as one that is breath-actuated.
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###### Results of the first (before training), second and third Vitalograph Aerosol Inhalation Monitor (AIM) tests after training
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###### pMDI technique using the Vitalograph Aerosol Inhalation Monitor (AIM) and GINA control
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###### First Vitalograph Aerosol Inhalation Monitor (AIM) test and prescription for short courses of oral steroids
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###### pMDI with and without spacer and GINA control
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###### GINA control vs BDP pMDI (Clenil and QVAR) vs QVAR Easi-Breathe
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